Liberum Capital Reaffirms Galliford Try PLC (LON:GFRD) As “Buy”; Has Target Price per Share Of GBX 1550.00; Summit Therapeutics plc (SMMT) Covered By 6 Bullish Analysts Last Week

London: In an analyst report issued to investors and clients on 15 January, Liberum Capital reiterated their “Buy” rating on shares of Galliford Try PLC (LON:GFRD). They currently have a GBX 1550.00 target price per share on the firm. Liberum Capital’s target would suggest a potential upside of 20.76% from the company’s previous stock close.

Among 7 analysts covering Summit Therapeutic (NASDAQ:SMMT), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Summit Therapeutic has $29 highest and $16 lowest target. $24.20’s average target is 90.85% above currents $12.6801 stock price. Summit Therapeutic had 10 analyst reports since August 19, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright on Friday, September 16 with “Buy”. Zacks downgraded Summit Therapeutics plc (NASDAQ:SMMT) on Tuesday, September 1 to “Hold” rating. The firm has “Buy” rating given on Thursday, June 15 by Canaccord Genuity. H.C. Wainwright maintained Summit Therapeutics plc (NASDAQ:SMMT) on Thursday, July 6 with “Buy” rating. Oppenheimer maintained Summit Therapeutics plc (NASDAQ:SMMT) on Thursday, June 22 with “Buy” rating. RBC Capital Markets maintained the shares of SMMT in report on Wednesday, November 16 with “Outperform” rating. The firm has “Buy” rating given on Friday, December 1 by H.C. Wainwright. Janney Capital initiated the shares of SMMT in report on Tuesday, June 21 with “Buy” rating. The firm earned “Buy” rating on Wednesday, August 19 by Oppenheimer. See Summit Therapeutics plc (NASDAQ:SMMT) latest ratings:

04/01/2018 Broker: SunTrust Rating: Buy New Target: $24 Initiates Coverage On
01/12/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $16 Reinitiate

The stock decreased 1.72% or GBX 22 during the last trading session, reaching GBX 1256. About 152,543 shares traded. Galliford Try plc (LON:GFRD) has 0.00% since January 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 9 analysts covering Galliford Try PLC (LON:GFRD), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Galliford Try PLC has GBX 1980 highest and GBX 830.20 lowest target. GBX 1506.80’s average target is 19.97% above currents GBX 1256 stock price. Galliford Try PLC had 71 analyst reports since September 14, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 14 by Beaufort Securities. The rating was maintained by Peel Hunt on Wednesday, May 3 with “Buy”. On Wednesday, November 22 the stock rating was maintained by Liberum Capital with “Buy”. The rating was maintained by Liberum Capital on Monday, November 20 with “Buy”. The rating was maintained by Peel Hunt on Friday, January 8 with “Buy”. The stock of Galliford Try plc (LON:GFRD) earned “Hold” rating by Jefferies on Monday, June 26. As per Wednesday, February 8, the company rating was maintained by HSBC. Canaccord Genuity maintained Galliford Try plc (LON:GFRD) on Tuesday, July 11 with “Hold” rating. The rating was maintained by Beaufort Securities on Friday, October 9 with “Buy”. The company was maintained on Friday, November 13 by Peel Hunt.

Galliford Try plc operates as a housebuilding and construction firm primarily in the United Kingdom. The company has market cap of 1.04 billion GBP. The firm develops and sells private and affordable homes under the Linden Homes brand name; and manufactures sustainable communities, as well as provides private housing for sale on regeneration-led sites. It has a 21.4 P/E ratio. It also undertakes infrastructure projects, including airports; coastal, defense, and harbors; commercial; custodial and judicial; data centers; education; energy from waste; assisted living; flood alleviation; ground engineering; health; highways; hotels; infrastructure security; leisure and cultural; gas and oil; rail; remediation; residential; retail; sports facilities and stadium; telecommunications; water; WI-FI and audio visual; and wind farm projects.

The stock increased 2.01% or $0.2501 during the last trading session, reaching $12.6801. About 42,506 shares traded or 15.74% up from the average. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since January 15, 2017 and is uptrending. It has outperformed by 16.52% the S&P500.